Novartis has agreed to buy Anthos Therapeutics from private equity firm Blackstone for $3.1 billion, adding a drug in ...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...

Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.

Bhatt also provided an overview of the negative results of the phase 3 OCEANIC-AF trial of asundexian (Bayer), a novel factor XIa inhibitor for the prevention of stroke and systemic embolism in ...

DiaMedica's DM199 shows promise for Acute Ischemic Stroke, but caution is advised due to low market cap and trial outcome uncertainties. See more on DMAC here.

Chronic Pain in the US: New Data In 2020, 25% of US adults with chronic pain managed their symptoms with medication alone versus nonpharmalogic treatments such as physical, occupational, or ...

Another novel agent, asundexian (Bayer). also has shown better than 90% inhibition of factor XI, with about 66% less bleeding compared with apixaban in patients with AF, as demonstrated in the PACIFIC ...

The study was funded by Anthos Therapeutics. Ruff disclosed personal grants and/or consulting relationships with Anthos, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi ...

DelveInsight’s Acute Myocardial Infarction Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. DelveInsight’s “Acute Myocardial Infarction Market ...

DelveInsight’s Acute Myocardial Infarction Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. DelveInsight’s “Acute Myocardial Infarction Market Insights, ...